Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Investigation of PJ vs. Sugar on Glucose Levels in Healthy and Prediabetic Subjects (PSW)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04591782
Recruitment Status : Active, not recruiting
First Posted : October 19, 2020
Last Update Posted : April 15, 2021
Sponsor:
Information provided by (Responsible Party):
Zhaoping Li, University of California, Los Angeles

Brief Summary:
Pomegranate fruits and products, including juice, tea, wine and extracts are widely consumed and recognized for their health benefits. Pomegranate fruit possesses strong antioxidant, anti-inflammatory and antiproliferative properties. The effects of pomegranate on type 2 diabetic (T2DM) conditions have previously been reported. Although 8 oz. of Pom juice (PJ) contains 36.9 g of sugar, 12-week PomJ supplementation did not change plasma advanced glycated end-products, fasting glucose and HbA1C, but reduced lipid peroxidation in T2D subjects. Additionally, acute PJ consumption has been shown to lower postprandial glycemic response of a meal with high glycemic index (GI) and lower fasting blood glucose, and long-term PomJ consumption did not worsen diabetic markers. However, a large knowledge gap still exists regarding the form of sugars in PJ and the hormonal responses to PJ consumption in different physiological conditions. Therefore currently the consumption of PJ is not recommended for individuals with T2DM. This clinical study will focus on the short-term effects of PJ consumption on different diabetic variables to further evaluate the health benefits of PJ for T2DM.

Condition or disease Intervention/treatment Phase
Diabete Type 2 Pre Diabetes Other: PomJuice Other: Water Other: Sugar Water Not Applicable

Detailed Description:
This study aims to measure the effects of PJ vs. sugar on glucose and insulin levels in apparently healthy normal weight and prediabetic overweight and obese subjects. Participants will be asked to consume one serving of PJ, sugar mix and water separated by one week of beige diet without PJ consumption (crossover design). The PJ will be provided by POMWonderful. Timed blood collections over a three-hour period following the juice/sugar/water consumption will be used to measure how PJ vs. sugar mix vs. water affects glucose metabolism/insulin sensitivity in human subjects.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 42 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Exploratory Study to Determine the Bioavailability of Sugar From Pomegranate Juice (PJ) vs. Sucrose
Actual Study Start Date : February 1, 2019
Estimated Primary Completion Date : December 20, 2021
Estimated Study Completion Date : December 20, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: PomJuice (PJ)
8 oz of PJ
Other: PomJuice
Drink 8 oz pomegranate juice

Active Comparator: Sugar Water
8 oz of water with 18.6 g of glucose + 18.3 g of fructose dissolved into it
Other: Sugar Water
Drink 8 oz of water with 18.6 g of glucose + 18.3 g of fructose dissolved in

Water
8 oz of water
Other: Water
Drink 8 oz water




Primary Outcome Measures :
  1. Number of participants with acute response to sugar water vs. pom juice vs. water [ Time Frame: 2 hours ]
    Compare the difference in blood glucose response to consuming PomJ compared to the same amount of sugar (fructose and glucose) mixed in water in a cross over study design

  2. Number of participants with hormonal changes in response to sugar water vs. pom juice vs. water [ Time Frame: 15 days ]
    Compare the plasma concentration of principle hormones involved in glucose regulation (insulin, C-peptide, glucagon) , gut hormones (GLP-1 and GIP) and triglycerides.

  3. Number of participants with acute response of plasma nitric oxide (NO) from sugar water vs. pom juice vs. water [ Time Frame: 2 hours ]
    Compare the acute response of plasma nitric oxide (NO) in participants who consume sugar alone, water alone or pomegranate juice

  4. Impact of gut microbiome in glycemic response to pom juice vs. sugar water [ Time Frame: 15 days ]
    Compare the glycemic response and the ability to form microbiote urolithin from pomegranate ellagatanins in participants who consume pom juice vs. water.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Age 20-50 years and any racial/ethnic group
  2. Typically consume low fiber/polyphenol diet (beige diet)
  3. Healthy, normal weight individuals with a BMI of >18 to 26.9 kg/ m2 with fasting serum glucose <100mg/dL or A1c <5.7
  4. Prediabetic, obese individuals with a BMI of >27 kg/ m2 and fasting serum glucose >100, but <126 mg/dL or A1c >5.7% but < 6.4%]
  5. Subjects must read and sign the informed consent prior to participation
  6. Subjects must be in generally good health
  7. Subjects must be able and willing to comply with the requirements of the protocol.

Exclusion Criteria:

  1. Eating a high fiber/polyphenol diet or taking any medication or dietary supplements that interfere with the absorption of polyphenols.
  2. History of gastrointestinal surgery, diabetes mellitus on medications, or other serious medical condition, such as chronic hepatic or renal disease, bleeding disorder, congestive heart disease, chronic diarrhea disorders, myocardial infarction, coronary artery bypass graft, angioplasty within 6 months prior to screening, current diagnosis of uncontrolled hypertension (defined as systolic BP >160mmHg, diastolic BP > 95mmHg), active or chronic gastrointestinal disorders, bulimia, anorexia, laxative abuse, or endocrine diseases (except thyroid disease requiring medication) as indicated by medical history
  3. Any subject currently taking blood thinning medications such as Warfarin or Coumadin
  4. Currently uses tobacco products.
  5. Currently has an alcohol intake > 20 g ⁄ day;
  6. Currently has a coffee intake > 3 cups ⁄ day;
  7. Screening laboratory value outside of the laboratory normal range that is considered clinically significant for study participation by the investigator.
  8. Using prebiotics, probiotics, yogurt, and/or any fiber supplements regularly
  9. Allergy or sensitivity to pomegranate. Subjects will be excluded if there is a prior history of such sensitivity. Since these foods are commonly eaten and allergies are rare, subjects should be aware of this sensitivity prior to entering the study. In addition, any subject with a history of allergy or anaphylaxis of any kind will be excluded
  10. Taking antibiotics or laxatives within the past 3 months
  11. Is unable or unwilling to comply with the study protocol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04591782


Locations
Layout table for location information
United States, California
UCLA Center for Human Nutrition, 1000 Veteran Ave.
Los Angeles, California, United States, 90095
Sponsors and Collaborators
University of California, Los Angeles
Investigators
Layout table for investigator information
Principal Investigator: Zhaoping Li, MD, PhD UCLA Professor of Medicine
Layout table for additonal information
Responsible Party: Zhaoping Li, Chief / Professor of Medicine, University of California, Los Angeles
ClinicalTrials.gov Identifier: NCT04591782    
Other Study ID Numbers: 18-001720
First Posted: October 19, 2020    Key Record Dates
Last Update Posted: April 15, 2021
Last Verified: April 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Zhaoping Li, University of California, Los Angeles:
pomegranate
antioxidants
prediabetes
Additional relevant MeSH terms:
Layout table for MeSH terms
Prediabetic State
Diabetes Mellitus, Type 2
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases